Agios Pharmaceuticals, Inc. (AGIO) vs Mesoblast Limited (MESO)
Agios Pharmaceuticals, Inc. and Mesoblast Limited are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Mesoblast Limited are of similar size ($2.0B and $2.0B). Agios Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 140.6% against −26.5%. Agios Pharmaceuticals, Inc. has the higher net margin (−418.2% vs −1,091.7%) and the lower return on invested capital (−70.2% vs 0.00%). Across the 18 metrics below, Agios Pharmaceuticals, Inc. leads on 9 and Mesoblast Limited on 9.
Valuation
Profitability
| Metric | AGIO | MESO | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.99% | (269.72%) | 65.16% |
| Operating margin | (466.78%) | (826.28%) | 0.00% |
| Net margin | (418.24%) | (1,091.71%) | 0.00% |
| Free cash flow margin | (371.43%) | 0.00% | 0.00% |
| Return on equity | (34.34%) | 0.00% | (57.72%) |
| Return on assets | (31.89%) | 0.00% | (49.22%) |
| Return on invested capital | (70.24%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack